SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshire Hathaway is trending as investors debate its massive cash pile and underperformance relative to the broader market, with many pinning their hopes on the upcoming annual meeting for clarity on CEO Greg Abels leadership strategy. Community sentiment is deeply divided between long-term supporters viewing the stock as a defensive value anchor and frustrated traders rotating into higher-growth AI and tech sectors.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending after reports surfaced that the company is preparing an offer to acquire eBay, fueling aggressive retail speculation about a potential strategic pivot into e-commerce. While the community is actively debating the feasibility of the merger given the valuation gap, the news has ignited significant options activity and excitement over a potential short squeeze.

Liquid Mercury is a technology company that provides institutional-grade trading infrastructure, workflow automation, and Real World Asset (RWA) marketplaces. Its platform is designed to meet the performance, security, and reporting standards expected by the most demanding traditional finance institutions.  At the core of the ecosystem is MERC, an ERC-20 utility token that delivers value to users in three primary ways:  1. Discount Farming via Staking  MERC holders can participate in a “Discount Farming Staking Program,” which enables users to earn monthly Element Tokens (ETs) by staking their MERC tokens. These ETs can be:  - Applied toward Liquid Mercury invoices for service discounts, if you're a customer. - Traded for cash equivalents on a private secondary marketplace where ET holders and Liquid Mercury customers can buy and sell ETs.  2. Access to Premium Features and Staking Rewards  Staking MERC also unlocks:  - Access to exclusive research, curated trading tools, and trading rebates. - Annual staking rewards paid in MERC, currently set at 10% per year.  3. Utility in the Expansion of Real World Asset (RWA) Markets  As Liquid Mercury grows its footprint in the RWA sector, the role of the MERC token will expand accordingly, powering participation and utility within tokenized asset marketplaces.

Liquid Mercury

Liquid Mercury is gaining traction as community members highlight continuous development updates, including new website features and the TokenBloq integration. Investors are actively tracking the project's institutional-grade infrastructure and its high-profile backing as part of broader ecosystem partnerships.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

$SPERMWHALE is trending as investors actively discuss its potential for rapid price surges, utility features like buybacks, and its status within the volatile meme coin community. The conversation is driven by a mix of speculative enthusiasm for breaking new all-time highs and persistent debate regarding the project's sustainability compared to other emerging tokens.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is currently a focal point for investors due to positive clinical data for its lead oral drug, Soquelitinib, which has fueled speculation regarding potential M&A activity and institutional accumulation. While the community is debating whether the stock is undergoing a healthy consolidation or a speculative pump, discussion remains heavily focused on upcoming clinical milestones and the potential for a major pharmaceutical acquisition.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Abivax is trending due to surging M&A speculation, with renewed reports from French media identifying Eli Lilly and AstraZeneca as potential suitors. The community is focused on the stock's M&A premium and recent positive data readouts, fueling intense interest in a possible high-value acquisition of the company's inflammatory disease platform.

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Vir Biotechnology Inc

Vir Biotechnology is trending as investors react to a significant strategic oncology collaboration with Astellas Pharma and strong clinical trial results for its prostate cancer drug, VIR-5500. While the community is actively debating the impact of a recent public stock offering and the potential for a short squeeze, many are focused on the long-term value of the company's strengthened cash position and its dual franchises.

Orca is the most user-friendly DEX on Solana.  Orca is one of the first general-purpose AMMs launched on Solana. Users can swap assets, provide liquidity, and earn yield through an easy-to-use interface. Projects can use Orca as a money-lego to easily integrate swapping, farming, or on-chain data into their dApp.  Orca strives to provide easy and effective financial tools for everyone, bringing DeFi to the masses.

Orca

Orca is trending due to significant community excitement surrounding its position as a leading Solana DEX and ongoing speculation about supply-driven price expansion. The community is actively discussing its low circulating supply, potential for long-term growth as the Solana ecosystem matures, and the impact of DAO-driven buyback initiatives.

Pershing Square, Inc. operates as an alternative asset management company. It operates through the following business segments: Operating Assets, MPC,and Strategic Developments. The Operating Assets segment consists of developed or acquired retail, office, and multifamily properties along with other real estate investments. The MPC segments offers the development and sale of land in large-scale, long-term community development projects. The Strategic Developments segment provides residential condominium and commercial property projects currently under development. The company was founded by William A. Ackman on December 17, 2003 and is headquartered in New York, NY.

Pershing Square Inc.

Pershing Square Inc

Pershing Square Inc. (PS) is generating intense buzz following a combined IPO with Pershing Square USA, with the community closely tracking Bill Ackmans commentary on the firm's structure and future growth strategy. Investors are actively debating the long-term potential of these vehicles, balancing excitement over Ackmans track record against concerns about IPO volatility and the complexities of the closed-end fund structure.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic remains a focal point for the community as investors debate the impact of potential burn mechanisms and the long-term viability of the chain's revival efforts. Discussions are heavily divided between those highlighting bullish technical patterns and opportunistic accumulation strategies, and others dismissing the asset as a speculative pump-and-dump venture.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings Growth

Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

M&T Bank Corp Acquires Shares of 83,348 Sarepta Therapeutics, Inc. $SRPT

M&T Bank Corp purchased a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and...

Sarepta Therapeutics (SRPT) Projected to Post Quarterly Earnings on Wednesday

Sarepta Therapeutics (NASDAQ:SRPT) will be releasing its Q1 2026 earnings after the market closes on Wednesday, May 6. (View Earnings Report at...

Ocugen Stock Outlook: Valuation, Cash Runway and Dilution Risk

Ocugen offers upside from a packed 2026 catalyst calendar, but cash runway limits and dilution risk keep the pre-commercial biotech outlook finely balanced.

OCGN's Gene-Agnostic Strategy Could Reset Retinal Therapy

Ocugen's gene-agnostic therapy strategy targets broad retinal patient groups with one-time treatments, setting up major 2026-27 catalyst events.

Sarepta Therapeutics to Announce First Quarter 2026 Financial Results

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2026 financial results after the Nasdaq Global Market closes on Wednesday, May 6, 2026. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss...

Sarepta Therapeutics, Inc. $SRPT Shares Purchased by Cwm LLC

Cwm LLC raised its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 230.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 240,536 shares of the biotechnology company's stock after purchasing...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Rating of "Hold" from Analysts

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) have earned an average rating of "Hold" from the twenty-eight research firms that are currently covering the firm, Marketbeat.com reports. Six research analysts have rated the stock with a sell recommendation, thirteen have assign...

KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment

Keros heads into 2026 with three key catalysts, including DMD study start, ALS regulatory talks, and Takeda progress, that could reshape investor sentiment.

KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026?

Keros reshaped its finances with a Takeda deal, boosting revenue and cutting R&D ??? but does it truly reduce dilution risk as 2026 uncertainty looms?

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

SRPT
Sarepta Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest SRPT News

SRPTSarepta Therapeutics Inc